AULDYN HIRSCHEY: Open Payments
NPI 1114176914 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,871 in 48 payments from 21 companies in 2025. Trend: 2023 $1,717 · 2024 $1,366 · 2025 $1,871
Long term medical supply or device loan: $1,000Food & beverage: $840Education: $32
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $1,027 |
| Janssen Biotech, Inc. | 3 | $184 |
| ARRAY BIOPHARMA INC | 5 | $94 |
| ABBVIE INC. | 3 | $61 |
| Celgene Corporation | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $47 |
| TerSera Therapeutics LLC | 2 | $42 |
| PFIZER INC. | 2 | $42 |
| Gilead Sciences, Inc. | 2 | $37 |
| JAZZ PHARMACEUTICALS INC. | 1 | $34 |
Products named: KISQALI, RYBREVANT, LORBRENA, REBLOZYL, Enhertu, Zoladex, EPKINLY, IBRANCE.
Industry payments across LA — which companies pay providers there.
